Sormani MP - Search Results

1

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: sormani mp. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.

2

Modelling the distribution of cortical lesions in multiple sclerosis.

Sormani M, Stromillo ML, Battaglini M, Signori A, De Stefano N. Sormani M, et al. Mult Scler. 2012 Feb;18(2):229-31. doi: 10.1177/1352458511414965. Epub 2011 Jul 14. Mult Scler. 2012. PMID: 21757533

3

Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies.

Sormani MP, Calabrese M, Signori A, Giorgio A, Gallo P, De Stefano N. Sormani MP, et al. PLoS One. 2011;6(10):e26712. doi: 10.1371/journal.pone.0026712. Epub 2011 Oct 20. PLoS One. 2011. PMID: 22028937 Free PMC article.

4

Indirect comparisons of treatment effects in multiple sclerosis.

Sormani MP, Signori A. Sormani MP, et al. Eur J Clin Pharmacol. 2012 Aug;68(8):1227-8; author reply 1225-6. doi: 10.1007/s00228-012-1246-1. Epub 2012 Feb 29. Eur J Clin Pharmacol. 2012. PMID: 22374347 No abstract available.

5

The quality of reports of randomized trials in multiple sclerosis: a review.

Signori A, Baccino A, Sormani MP. Signori A, et al. Among authors: sormani mp. Mult Scler. 2012 Jun;18(6):776-81. doi: 10.1177/1352458512444327. Epub 2012 Apr 11. Mult Scler. 2012. PMID: 22495947 Review.

6

Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.

Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE. Laroni A, et al. Among authors: sormani mp. J Neuroimmune Pharmacol. 2012 Sep;7(3):665-72. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16. J Neuroimmune Pharmacol. 2012. PMID: 22585413

7

Time to first relapse as an endpoint in multiple sclerosis clinical trials.

Sormani MP, Signori A, Siri P, De Stefano N. Sormani MP, et al. Mult Scler. 2013 Apr;19(4):466-74. doi: 10.1177/1352458512457841. Epub 2012 Aug 22. Mult Scler. 2013. PMID: 22914849

8

Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.

Verhey LH, Signori A, Arnold DL, Bar-Or A, Sadovnick AD, Marrie RA, Banwell B, Sormani MP. Verhey LH, et al. Among authors: sormani mp. Neurology. 2013 Oct 1;81(14):1215-21. doi: 10.1212/WNL.0b013e3182a6cb9b. Epub 2013 Aug 21. Neurology. 2013. PMID: 23966255 Free PMC article.

9

Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.

Sormani MP, De Stefano N. Sormani MP, et al. Neurology. 2014 Apr 29;82(17):1484-5. doi: 10.1212/WNL.0000000000000369. Epub 2014 Mar 28. Neurology. 2014. PMID: 24682968 No abstract available.

10

Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.

Laroni A, Gandoglia I, Solaro C, Ribizzi G, Tassinari T, Pizzorno M, Parodi S, Baldassarre G, Rilla MT, Venturi S, Capello E, Sormani MP, Uccelli A, Mancardi GL. Laroni A, et al. Among authors: sormani mp. BMC Neurol. 2014 May 12;14:103. doi: 10.1186/1471-2377-14-103. BMC Neurol. 2014. PMID: 24885703 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

487 results

Search Page